Pacific Biosciences of California (PACB) stock rises despite market decline

From Nasdaq: 2024-06-28 18:15:21

Pacific Biosciences of California (PACB) closed at $1.37, up 0.74%, outperforming the S&P 500. Shares fell by 29.9% in the past month, lagging behind the Medical sector and S&P 500. Earnings per share are estimated to be -$0.24, with revenue projected at $40.52 million. Analysts expect earnings of -$0.91 per share for the full year.

The Zacks Rank system shows a 0.58% rise in EPS estimate in the past month for PACB, currently ranked at #3 (Hold). The Medical – Instruments industry has a Zacks Industry Rank of 163, placing it in the bottom 36%. Zacks research shows that industry performance significantly affects stock returns.

Investors should stay updated on stock-moving metrics using Zacks.com. Analysts’ estimates and revisions directly impact stock prices. Analyst sentiment can be gauged through the Zacks Rank, which has a track record of superior performance. Stay informed to make informed investment decisions and maximize returns.



Read more at Nasdaq: Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors